123 related articles for article (PubMed ID: 33527588)
1. Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity score-matched study using the Korean Renal Cancer Study Group database.
Lee CH; Chung J; Kwak C; Jeong CW; Seo SI; Kang M; Hong SH; Song C; Park JY; Hwang EC; Lee H; Ku JY; Seo WI; Choi SH; Ha HK;
Int J Urol; 2021 Apr; 28(4):417-423. PubMed ID: 33527588
[TBL] [Abstract][Full Text] [Related]
2. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
3. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O; Inanc M; Hacibekıroglu I; Esbah O; Seker M; Ulas A; Aydin K; Uysal M; Kücüköner M; Uncu D; Cıltas A; Unal OÜ; Durnali A; Demırcı U; Berk V; Tonyali O; Oksüzoglu B; Karaca H; Ozkan M
Anticancer Res; 2014 Aug; 34(8):4463-70. PubMed ID: 25075086
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery.
Kobayashi K; Saito T; Kitamura Y; Bilim V; Toba T; Kawasaki T; Hara N; Tanikawa T; Tomita Y
Int J Urol; 2016 Feb; 23(2):132-7. PubMed ID: 27688158
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kyriakopoulos CE; Chittoria N; Choueiri TK; Kroeger N; Lee JL; Srinivas S; Knox JJ; Bjarnason GA; Ernst SD; Wood LA; Vaishampayan UN; Agarwal N; Pal SK; Kanesvaran R; Rha SY; Yuasa T; Donskov F; North SA; Heng DY; Rini BI
Clin Genitourin Cancer; 2015 Apr; 13(2):e79-85. PubMed ID: 25450036
[TBL] [Abstract][Full Text] [Related]
7. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
8. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
[TBL] [Abstract][Full Text] [Related]
9. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).
Brookman-May SD; May M; Shariat SF; Novara G; Zigeuner R; Cindolo L; De Cobelli O; De Nunzio C; Pahernik S; Wirth MP; Longo N; Simonato A; Serni S; Siracusano S; Volpe A; Morgia G; Bertini R; Dalpiaz O; Stief C; Ficarra V; ; ;
BJU Int; 2013 Nov; 112(7):909-16. PubMed ID: 23890378
[TBL] [Abstract][Full Text] [Related]
10. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
[TBL] [Abstract][Full Text] [Related]
11. Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis.
Xing H; Sun LY; Yan WT; Quan B; Liang L; Li C; Zhou YH; Wang H; Zhong JH; Gu WM; Chen TH; Wang MD; Wu H; Pawlik TM; Lau WY; Wu MC; Shen F; Yang T
Surgery; 2021 Apr; 169(4):911-920. PubMed ID: 31879090
[TBL] [Abstract][Full Text] [Related]
12. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis.
Chang X; Zhang F; Liu T; Wang W; Guo H
Int Urol Nephrol; 2017 Jun; 49(6):967-974. PubMed ID: 28247169
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factor for Korean patients with renal cell carcinoma and venous tumor thrombus extension: application of the new 2009 TNM staging system.
Cho MC; Kim JK; Moon KC; Kim HH; Kwak C
Int Braz J Urol; 2013; 39(3):353-63. PubMed ID: 23849567
[TBL] [Abstract][Full Text] [Related]
16. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients.
Yu J; Zhang X; Liu H; Zhang R; Yu X; Cheng Z; Han Z; Liu F; Hao G; Mu MJ; Liang P
Radiology; 2020 Mar; 294(3):698-706. PubMed ID: 31961239
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
20. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
